Evidence memo / GH / IGF axis

CJC-1295 with DAC claims

Also: CJC-1295 DAC · drug affinity complex GHRH analog · long-acting GHRH analog

CJC-1295 with DAC is a long-acting version of a growth-hormone-releasing hormone analog. The DAC part lets it bind to albumin in the blood so it lasts for days instead of minutes. One small published study in healthy volunteers showed it raises growth hormone and IGF-1 for about a week per dose. Beyond that early pharmacology there are no trials showing it improves body composition, strength, or any health outcome, and it is not an approved drug. The Watchlist boundary is keeping this to the limited human pharmacology it actually has and not treating raised hormone levels as proof of benefit.

Early human signalEarly human signalSafety / regulatory watch

The verdict

Our read at a glance.

Whether CJC-1295 with DAC, which raises growth hormone and IGF-1 in early studies, produces the muscle, fat-loss, and recovery benefits marketed for it.

The signal
A small early study in healthy adults showed CJC-1295 with DAC produces a sustained rise in growth hormone and IGF-1 lasting several days per dose. There are no controlled trials testing whether that translates into changes in body composition, strength, recovery, or long-term safety.
The unknown
Whether the sustained rise in growth hormone and IGF-1 does anything useful or is safe over time, since chronically elevated IGF-1 carries its own theoretical risks.
Our read
Real but shallow human pharmacology, no outcome evidence. CJC-1295 with DAC clearly raises growth hormone and IGF-1 for days, but no study shows that helps body composition or recovery, and its safety over time is unknown.

The mechanism

How it works.

CJC-1295 is a modified fragment of growth-hormone-releasing hormone, the brain signal that tells the pituitary to release growth hormone. The DAC, or drug affinity complex, is a chemical group that attaches the peptide to albumin in the blood so it is not cleared within minutes, stretching its action to several days. While bound, it keeps prompting the pituitary, producing a sustained rise in growth hormone and IGF-1. This pharmacology is documented in a small human study, but whether that pattern of stimulation is useful or safe over the long term has not been established.

Safety & regulatory boundary

The consequential part.

CJC-1295 with DAC is not an approved medicine and is sold as a research chemical, where identity, purity, and dose are uncertain. Its only human data is a short pharmacology study, not evidence of benefit. Sustained elevation of growth hormone and IGF-1 is not the same as a proven therapy, and the long-term safety of pushing these hormones up for months or years has not been studied.

What's next

What we're watching.

Whether any controlled trial ever tests it for an actual outcome rather than just hormone levels, and any long-term safety data on sustained IGF-1 elevation.

Context

Why this is discussed.

It promises the effects of growth hormone from an infrequent injection by pushing the body to make its own, which appeals to people seeking muscle, fat loss, and anti-aging effects.

The evidence base

13 cited references.

Registered trials1

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

ClinicalTrials.gov · PHASE2 · TERMINATED · 2005-12

Indexed literature (PubMed)12

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

Rahman OF et al. · J Am Acad Orthop Surg Glob Res Rev · 2026

Keep reading

Related published memos.